Who is sponsoring NCT03739580?

NCT03739580 is sponsored by Xuanwu Hospital, Beijing.

What drugs are being tested in NCT03739580?

Interventions in NCT03739580: DCB angioplasty (Orchid, Acotec Scientific Co. Ltd.), Stent (Maris,Medtronic.USA or Sinus/Supera, Germany).

What condition does NCT03739580 study?

NCT03739580 studies Popliteal Stenosis, Popliteal Artery Occlusion, Diabetes.

Is NCT03739580 still recruiting?

NCT03739580 is currently status unknown. Last updated 14 November 2018.

Last reviewed 2018-11-14 · How we verify

NCT03739580

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DCB Compared Stenting in Popliteal Lesions

Status unknown NA Last updated 14 November 2018

What this trial tests

NA trial testing DCB angioplasty (Orchid, Acotec Scientific Co. Ltd.) in Popliteal Stenosis in 80 participants. Status unknown.

Timeline

1 October 2016

Primary endpoint
1 December 2018

1 September 2019

Quick facts

Lead sponsor	Xuanwu Hospital, Beijing
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	1 October 2016
Primary completion	1 December 2018
Estimated completion	1 September 2019
Sites	1 location across China

Drugs / interventions tested

DCB angioplasty (Orchid, Acotec Scientific Co. Ltd.)
Stent (Maris,Medtronic.USA or Sinus/Supera, Germany)

Conditions studied

Popliteal Stenosis — all drugs for Popliteal Stenosis →
Popliteal Artery Occlusion — all drugs for Popliteal Artery Occlusion →
Diabetes — all drugs for Diabetes →

Sponsor

Xuanwu Hospital, Beijing

Who can join

Adults 18 to 80, any sex, with Popliteal Stenosis or Popliteal Artery Occlusion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized prospective study aiming to compare drug-coated balloons and stent deployment in Popliteal atherosclerotic occlusive lesions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Xuanwu Hospital, Beijing trials

Trials by the same sponsor.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03739580 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
Last refreshed: 14 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03739580.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing